Small-molecule tyrosine kinase inhibitors of epidermal growth factor receptor (EGFR)

Japanese Journal of Cancer and Chemotherapy

Volumn 36, Issue 7, 2009, Pages 1058-1062

  Mitsudomi, Tetsuya ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; CANCER GENETICS; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; HUMAN; LUNG CANCER; MUTATION;

EID: 79959831031     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Hynes NE and Lane HA: ERBB receptors and cancer the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354, 2005. (Pubitemid 40637826)
2. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004. (Pubitemid 38637993)
3. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004. (Pubitemid 38720929)
4. Matsuo K, Ito H, Yatabe Y, et al: Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese. Cancer Sci 98: 96-101, 2006. (Pubitemid 44803926)
5. Mitsudomi T and Yatabe Y: Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 98: 1817-1824, 2007.
6. Ji H, Li D, Chen L, et al: The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 9: 485-495, 2006. (Pubitemid 43832191)
7. Politi K, Zakowski MF, Fan PD, et al: Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 20: 1496-1510, 2006.
8. Weinstein IB: Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 297: 63-64, 2002.
9. Yun CH, Boggon TJ, Li Y, et al: Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11: 217-227, 2007. (Pubitemid 46349842)
10. Cappuzzo F, Hirsch FR, Rossi E, et al: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst 97: 643-655, 2005. (Pubitemid 40812628)
11. Varella-Garcia M, Mitsudomi T, Yatabe Y, et al: EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort. J Thorac Oncol 4: 318-325, 2009.
12. Thatcher N, Chang A, Parikh P, et al: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366: 1527-1537, 2005. (Pubitemid 41540110)
13. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132, 2005. (Pubitemid 41058344)
14. Maruyama R, Nishiwaki Y, Tamura T, et al: Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 26: 4244-4252, 2008.
15. Kim ES, Hirsh V, Mok T, et al: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372: 1809-1818, 2008.
16. Mok T, Wu Y-L, Thongprassert S, et al: Phase III, randomized, open-label, first-line study of gefitinib vs carboplatin/paclitaxel in clinically selected patients with advanced non-small cell lung cancer (ESMO 2008, LBA2). Ann Oncol 19(Suppl 8): viii1, 2008.
17. Kobayashi S, Boggon TJ, Dayaram T, et al: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792, 2005.
18. Pao W, Miller VA, Politi KA, et al: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73, 2005.
19. Yun CH, Mengwasser KE, Toms AV, et al: The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 105: 2070-2075, 2008.
20. Toyooka S, Kiura K and Mitsudomi T: EGFR mutation and response of lung cancer to gefitinib. N Engl J Med 352: 2136; author reply 2136, 2005.
21. Bell DW, Gore I, Okimoto RA, et al: Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 37: 1315-1316, 2005.
22. Regales L, Balak MN, Gong Y, et al: Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PLoS ONE 2: e810, 2007.
23. Suda K, Onozato R. Yatabe Y, et al: EGFR T790M mutation: a double role in lung cancer cell survival? J Thorac Oncol 4: 1-4, 2009.
24. Bean J, Brennan C, Shih JY, et al: MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104: 20932-20937, 2007.
25. Engelman JA, Zejnullahu K, Mitsudomi T, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043, 2007.
26. Li D, Ambrogio L, Shimamura T, et al: BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in pre-clinical lung cancer models. Oncogene 27: 4702-4711, 2008.
27. Engelman JA, Zejnullahu K, Gale CM, et al: PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 67: 11924-11932, 2007.
28. Kosaka T, Yatabe Y, Endoh H, et al: Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 12: 5764-5769, 2006.